Android Apple

Biomea Fusion, Inc. (BMEA): Why Did Analysts Give This Biotech Penny Stock a Moderate Buy Rating?

By Yahoo! Finance   |   5 months ago
Biomea Fusion, Inc. (BMEA): Why Did Analysts Give This Biotech Penny Stock a Moderate Buy Rating?

A list of top biotech penny stocks includes Biomea Fusion, Inc. (NASDAQ:BMEA), a company developing treatments for cancers and metabolic diseases. Despite setbacks, BMEA shows potential for growth with a 353.86% price target increase.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.